Carcinoma, Non-Small-Cell Lung

Showing 26 - 50 of 574

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

Circulating Tumor DNA and T Cell Repertoire Predict

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Brain Metastases
  • Whole-brain radiotherapy
  • Wuhan, Hubei, China
    Union hospital
Feb 12, 2023

NSCLC Trial in Washington, Hackensack, Neptune (Nivolumab, Ipilimumab, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Washington, District of Columbia
  • +2 more
Jan 27, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Montanide (Registered Trademark) ISA-51 VG Adjuvant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +8 more
Jan 31, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +83 more
Jan 31, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Worldwide (Dexamethasone, Montelukast, Methotrexate)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Fountain Valley, California
  • +17 more
Jan 31, 2023

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Nivolumab
  • +6 more
  • Tampa, Florida
  • +112 more
Jan 30, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

NSCLC Trial in Worldwide (Entrectinib, Crizotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Barretos, SP, Brazil
  • +66 more
Jan 27, 2023

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

Ovarian Tumors, Endometrial Tumors, NSCLC Trial in United Kingdom, United States (SGN-ALPV)

Recruiting
  • Ovarian Neoplasms
  • +5 more
  • Fresno, California
  • +10 more
Jan 20, 2023

NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Chicago, Illinois
  • +140 more
Jan 20, 2023

NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sasanlimab Prefilled syringe
  • +5 more
  • Duarte, California
  • +96 more
Jan 18, 2023

NSCLC Trial in Worldwide (MORAb-202)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Lone Tree, Colorado
  • +21 more
Jan 17, 2023

NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Glendale, Arizona
  • +33 more
Jan 12, 2023

NSCLC Trial in Worldwide (AZD7789)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Atlanta, Georgia
  • +8 more
Jan 12, 2023

KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)

Recruiting
  • KRAS G12C Mutant Solid Tumors
  • +10 more
  • Boston, Massachusetts
  • +5 more
Jan 11, 2023

NSCLC Trial in Amsterdam (Ipilimumab, Cemiplimab, SBRT)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoek - Netherlands Cancer Institute
Jan 10, 2023

NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • Docetaxel
  • Beijing, China
  • +37 more
Jan 9, 2023